|1.||Reitamo, Sakari: 17 articles (08/2014 - 01/2002)|
|2.||Ruzicka, T: 17 articles (12/2009 - 01/2000)|
|3.||Mutoh, Seitaro: 15 articles (02/2009 - 12/2002)|
|4.||Reitamo, S: 14 articles (08/2009 - 08/2000)|
|5.||Jaracz, Eileen: 13 articles (12/2008 - 10/2002)|
|6.||Remitz, Anita: 12 articles (08/2014 - 01/2002)|
|7.||Champlin, Richard E: 11 articles (04/2013 - 11/2003)|
|8.||Furue, Masutaka: 11 articles (05/2012 - 10/2003)|
|9.||Fleischer, Alan B: 11 articles (05/2010 - 10/2002)|
|10.||Antin, Joseph H: 10 articles (10/2015 - 09/2003)|
|1.||Atopic Dermatitis (Atopic Eczema)
07/01/2008 - "The proportion of dendritic cell subpopulations in the skin is important for the severity of atopic dermatitis because topical treatment with tacrolimus leads to rapid depletion of inflammatory dendritic epidermal cells, whereas Langerhans cells (LCs) predominate in cured sites. "
05/01/2007 - "Tacrolimus applied locally is a non-steroid anti-inflammatory drug with proven efficacy in atopic dermatitis. "
07/01/2006 - "In view of its strong association with atopic dermatitis, the objective of this open-label study was to assess the efficacy and safety of tacrolimus ointment in the treatment of PA compared with the efficacy of moisturizers. "
09/01/2005 - "At the end of study, 50.6% (80 of 158) of the patients were treated successfully with tacrolimus ointment based on Investigators' Global Atopic Dermatitis Assessment scores, a significant improvement compared with patients treated with vehicle ointment (25.8% [41 of 159]). "
01/01/2001 - "Moderate to severe atopic dermatitis significantly improved (measured using multiple end-points, including > or = 90% improvement in Physician's Global Evaluation of Clinical Response) with tacrolimus 0.03 and 0.1% ointment compared with vehicle in both adult (n = 304 and 328) and pediatric (n = 351) patients in three 12-week, double-blind, randomized, phase III trials. "
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
09/01/2005 - "Proven efficacy of tacrolimus for facial and intertriginous psoriasis."
04/01/1996 - "At the end of week 9, tacrolimus+-treated patients had a significantly greater reduction in the Psoriasis Area and Severity Index than did placebo-treated patients (tacrolimus, -83; placebo, -47; P<.02). "
03/01/2005 - "Based on the available literature and illustrated by the present case we may conclude that tacrolimus ointment 0.1% can be recommended as a first-line treatment for facial psoriasis."
02/01/2011 - "Tacrolimus is effective in treatment of psoriasis vulgaris. "
12/01/2010 - "FK506 is moderately effective in chronic plaque-type psoriasis in our model. "
01/01/2011 - "A novel tacrolimus topical ointment has shown remarkable efficacy in treating skin inflammation. "
12/01/2009 - "Intriguingly, treatment with topical tacrolimus 0.03% led to marked improvement in the inflammation on the legs but had little effect on the scalp."
02/05/2007 - "Repeated topical application of 2.5 microM of TS-022 and 12.5 microM of FK-506 once a day for 6 weeks significantly improved the skin inflammation scores in the NC/Nga mice. "
01/01/2000 - "Daily administration of FK506 initiated during the remission phase significantly attenuated the onset and development of chronic joint inflammation. "
12/01/2013 - "Tacrolimus is effective for the maintenance of refractory UC and can deliver sustained improvement in mucosal inflammation."
03/01/2011 - "Tacrolimus (Tac) is effective in the treatment of steroid-refractory ulcerative colitis (UC); however, nonresponse and unpredictable side effects are major limitations. "
01/01/2015 - "Oral tacrolimus therapy is effective for refractory ulcerative colitis (UC), but dose adjustment according to the trough concentrations which varies largely among individuals, is required. "
09/01/2008 - "Long-term administration of tacrolimus appears to be an effective and well-tolerated treatment for Japanese patients with refractory ulcerative colitis."
01/01/2008 - "Tacrolimus may be effective for short-term clinical improvement in patients with refractory ulcerative colitis. "
07/01/2011 - "Although the efficacy of tacrolimus for inducing remission of refractory ulcerative colitis (UC) is established, its efficacy for maintaining remission of UC has not been evaluated. "
04/01/2015 - "Our study shows that twice-weekly application of 0.1% tacrolimus ointment is effective in preventing the depigmentation of vitiligo patches that have been previously successfully repigmented."
12/01/2011 - "According to this study, the combination of NB-UVB and tacrolimus ointment (0.1%) is more effective than UV treatment alone in patients with vitiligo. "
05/01/2011 - "Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color."
01/01/2009 - "Patients with vitiligo for more than 5 years also responded well to tacrolimus ointment. "
04/01/2015 - "We hypothesized that a twice-weekly application of 0.1% tacrolimus ointment might be effective for maintaining repigmentation in therapeutically repigmented lesions of vitiligo patients. "
|6.||Adrenal Cortex Hormones (Corticosteroids)
|7.||mycophenolate mofetil (Cellcept)
|2.||Transplantation (Transplant Recipients)
|4.||Homologous Transplantation (Allograft)